SequelSEC

PMGC Holdings Inc. ELAB

Pharmaceutical Preparations · CIK 0001840563 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$2.58M
Fiscal year ended 2026-06-30
Operating income
Unavailable
Fiscal year ended 2026-06-30
Free cash flow
Unavailable
Fiscal year ended 2026-06-30

PMGC Holdings Inc. (ELAB) reported revenue of $2.58M and net income of -$13.49M for the fiscal year ended 2026-06-30. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from PMGC Holdings Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

PMGC Holdings Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Revenue$2.58M
Cost of revenue$1.78M
Gross profit$801.48K
Operating incomeUnavailable
Net income-$13.49M
Research & development$405.18K
Weighted-average diluted sharesUnavailable
Pretax incomeUnavailable
Income tax expenseUnavailable
Diluted EPSUnavailable
Selling, general & administrativeUnavailable
General & administrative$4.70M
Selling & marketingUnavailable

Balance

PMGC Holdings Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Cash & equivalentsUnavailable
Total assets$36.56M
Current assets$20.83M
Total liabilities$19.83M
Current liabilities$15.33M
Total equity incl. NCI$16.74M
Temporary (mezzanine) equityUnavailable
Inventory$932.51K
Accounts receivable$421.86K
Goodwill$3.04M
Long-term debtUnavailable
Accounts payableUnavailable

Cash flow

PMGC Holdings Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Operating cash flowUnavailable
Capital expendituresUnavailable
Investing cash flowUnavailable
Financing cash flowUnavailable
Net change in cashUnavailable
Stock-based compensationUnavailable
Common dividends paidUnavailable
Common share repurchasesUnavailable
Depreciation & amortization$535.72K

Derived

PMGC Holdings Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Free cash flowUnavailable
Gross margin31.1%
Operating marginUnavailable
FCF marginUnavailable
SBC / revenueUnavailable
Current ratio1.36x
Revenue YoY growthUnavailable
Net margin-523.0%
R&D / revenue15.7%
CapEx / revenueUnavailable
Long-term debt / equityUnavailable
Effective tax rateUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open ELAB in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-14View SEC filing
10-Q · Filed 2026-05-15View SEC filing
10-K · Filed 2026-03-30View SEC filing
10-Q · Filed 2025-11-14View SEC filing
10-Q · Filed 2025-08-13View SEC filing
10-Q · Filed 2025-05-14View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.